GLENMARK PHARMACEUTICALS
Back to Balance Sheet
|
GLENMARK PHARMACEUTICALS Last 5 Year Total Current Liabilities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Total Current Liabilities | ₹6,376 Cr | ₹5,967 Cr | ₹5,819 Cr | ₹4,546 Cr | ₹4,689 Cr |
What is the latest Total Current Liabilities ratio of GLENMARK PHARMACEUTICALS ?
| Year | Total Current Liabilities |
|---|---|
| Mar2026 | ₹6,376 Cr |
| Mar2025 | ₹5,967 Cr |
| Mar2024 | ₹5,819 Cr |
| Mar2023 | ₹4,546 Cr |
| Mar2022 | ₹4,689 Cr |
How is Total Current Liabilities of GLENMARK PHARMACEUTICALS Trending?
| Years | Total Current Liabilities | % Change | |
|---|---|---|---|
| Mar2026 | ₹6,376 Cr | 6.86 | |
| Mar2025 | ₹5,967 Cr | 2.55 | |
| Mar2024 | ₹5,819 Cr | 27.99 | |
| Mar2023 | ₹4,546 Cr | -3.05 | |
| Mar2022 | ₹4,689 Cr | - | |
Compare Total Current Liabilities of peers of GLENMARK PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLENMARK PHARMACEUTICALS | ₹67,586.9 Cr | 6.2% | 9.1% | 22.7% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹459,952.0 Cr | 1% | -2.9% | 17.4% | Stock Analytics | |
| DIVIS LABORATORIES | ₹230,427.0 Cr | 1.8% | 17% | 39.7% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹187,141.0 Cr | -1.9% | -1.9% | 33.2% | Stock Analytics | |
| CIPLA | ₹114,715.0 Cr | 0.3% | 0.7% | -7.4% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹99,409.9 Cr | 1.7% | 3.5% | -4.1% | Stock Analytics | |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLENMARK PHARMACEUTICALS | 6.2% |
9.1% |
22.7% |
| SENSEX | 0.5% |
2.1% |
-4.5% |
You may also like the below Video Courses